pubmed.ncbi.nlm.nih.gov

Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial - PubMed

️Fri Jan 01 1999

Clinical Trial

Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial

S Z Wiktor et al. Lancet. 1999.

Abstract

Background: In Africa, the risk of mother-to-child transmission of HIV-1 infection is high. Short-course perinatal oral zidovudine might decrease the rate of transmission. We assessed the safety and efficacy of such a regimen among HIV-1-seropositive breastfeeding women in Abidjan, Côte d'Ivoire.

Methods: From April, 1996, to February, 1998, all consenting, eligible HIV-1-seropositive pregnant women attending a public antenatal clinic in Abidjan were enrolled at 36 weeks' gestation and randomly assigned placebo or zidovudine (300 mg tablets), one tablet twice daily until the onset of labour, one tablet at onset of labour, and one tablet every 3 h until delivery. We used HIV-1-DNA PCR to test the infection status of babies at birth, 4 weeks, and 3 months. We stopped the study on Feb 18, 1998, when efficacy results were available from a study in Bangkok, Thailand, in which the same regimen was used in a non-breastfeeding population.

Findings: 280 women were enrolled (140 in each group). The median duration of the prenatal drug regimen was 27 days (range 1-80) and the median duration of labour was 7.5 h. Treatment was well tolerated with no withdrawals because of adverse events. All babies were breastfed. Among babies with known infection status at age 3 months, 30 (26.1%) of 115 babies in the placebo group and 19 (16.5%) of 115 in the zidovudine group were identified as HIV-1 infected. The estimated risk of HIV-1 transmission in the placebo and zidovudine groups were 21.7% and 12.2% (p=0.05) at 4 weeks, and 24.9% and 15.7% (p=0.07) at 3 months. Efficacy was 44% (95% CI -1 to 69) at age 4 weeks and 37% (-5 to 63) at 3 months.

Interpretation: Short-course oral zidovudine was safe, well tolerated, and decreased mother-to-child transmission of HIV-1 at age 3 months. Substantial efforts will be needed to ensure successful widespread implementation of such a regimen.

PubMed Disclaimer

Comment in

Combatting HIV and AIDS in sub-Saharan Africa.
Manfrin V. Manfrin V. Lancet. 2001 Apr 28;357(9265):1364-5. doi: 10.1016/s0140-6736(00)04489-5. Lancet. 2001. PMID: 11347583 No abstract available.

Cited by

Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models.
Rollins N, Mahy M, Becquet R, Kuhn L, Creek T, Mofenson L. Rollins N, et al. Sex Transm Infect. 2012 Dec;88 Suppl 2(Suppl_2):i44-51. doi: 10.1136/sextrans-2012-050709. Sex Transm Infect. 2012. PMID: 23172345 Free PMC article.
Treatment of HIV infection in pregnant women: antiretroviral management options.
Loutfy MR, Walmsley SL. Loutfy MR, et al. Drugs. 2004;64(5):471-88. doi: 10.2165/00003495-200464050-00002. Drugs. 2004. PMID: 14977385 Review.
Operational effectiveness of single-dose nevirapine in preventing mother-to-child transmission of HIV.
Colvin M, Chopra M, Doherty T, Jackson D, Levin J, Willumsen J, Goga A, Moodley P; Good Start Study Group. Colvin M, et al. Bull World Health Organ. 2007 Jun;85(6):466-73. doi: 10.2471/blt.06.033639. Bull World Health Organ. 2007. PMID: 17639244 Free PMC article.
Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies.
Stringer JS, Sinkala M, Rouse DJ, Goldenberg RL, Vermund SH. Stringer JS, et al. Am J Public Health. 2002 Mar;92(3):365-6. doi: 10.2105/ajph.92.3.365. Am J Public Health. 2002. PMID: 11867311 Free PMC article.

Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial - PubMed